Highlights Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Delayed Bombay S.E. Other stock markets 06:00:48 2024-04-30 am EDT			5-day change	1st Jan Change
891.6 ^INR	-0.34%		+0.91%	-2.09%

Apr. 03	Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	MT
Mar. 15	Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	Apr. 02	MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	Mar. 15	MT
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	Mar. 14	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	Mar. 14	RE
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	Mar. 13	CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	Feb. 15	MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	Feb. 14	CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	Feb. 13	CI
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	Feb. 12	CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	Feb. 08	RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	Nov. 09	CI
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	Nov. 08	CI
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 08	CI
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.	Nov. 07	CI
Eris Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-07	CI
Eris Lifesciences Gains Dermatology Trademarks Acquired from Glenmark via Deal with Unit Eris Oaknet	23-07-03	MT
Eris Lifesciences' Consolidated Profit Falls in Fiscal Q4	23-05-17	MT
Eris Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-17	CI
Eris Lifesciences Completes Acquisition of Nine Dermatology Brands from Dr. Reddy's	23-03-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Highlights

Filters